Last reviewed · How we verify
Avamys aqueous nasal spray 110mcg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Avamys aqueous nasal spray 110mcg (Avamys aqueous nasal spray 110mcg) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Avamys aqueous nasal spray 110mcg TARGET | Avamys aqueous nasal spray 110mcg | GlaxoSmithKline | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Avamys aqueous nasal spray 110mcg CI watch — RSS
- Avamys aqueous nasal spray 110mcg CI watch — Atom
- Avamys aqueous nasal spray 110mcg CI watch — JSON
- Avamys aqueous nasal spray 110mcg alone — RSS
Cite this brief
Drug Landscape (2026). Avamys aqueous nasal spray 110mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/avamys-aqueous-nasal-spray-110mcg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab